This is my third Ultragenyx (NASDAQ: RARE ) article, following 03/2024's "Ultragenyx Pharmaceutical Earnings: No Visible Path To Financial Success Yet". Ultragenx has had a rough go since the publication of No Visible Path , with itsWriting under the pseudonym "out of ignorance", I very much regard investing as a learning process. Investing failures are tuition paid. Investing successes enter the trove of lessons learned. In my Seeking Alpha articles I share my experience from decades of investing and from ...

投资观点 - 作者对UroGen Pharma持有多头仓位 包括股票所有权 期权或其他衍生品 [2] - 作者可能在72小时内买卖所提及公司的权益 [3] 作者背景 - 作者拥有数十年投资经验 近5年专注于股票研究 近年主要关注医疗保健类股票 [1] - 作者以"out of ignorance"为笔名 将投资视为学习过程 投资失败是学费 成功则是经验积累 [1] 文章性质 - 文章表达作者个人观点 未获得除Seeking Alpha外的其他报酬 [2] - 作者与文中提及公司无业务关系 [2]